"Medical headline king" national raid! Supplies rebates, notes, accounts.

(2020/07/23) treatment of nAMD Roche Rezhu single anti-glass implant 98% of patients to achieve a six-month interval of drug administration; after three tape procurement of a pharmaceutical company sales choice resignation; Huahai hair soar! Take 6 heavyweight varieties 21 overrated varieties bar screen ... (Click on the title, can get the original text) (Pharmaceutical 1st time) treatment of nAMD Roche Rejure monoanti-glass implant 98% of patients to achieve the six-month time interval before the date, Roche announced the detailed results of the Phase III ARCHWAY trial.
this random, multicenter, open-label study was conducted in 418 patients with neonatal vascular (wet) age-related macular degeneration (nAMD), who received at least three anti-VEGF injections in the six months prior to the study screening and were shown to be responsive to VEGF therapy.
headline: This will greatly reduce the patient's treatment burden.
eight-point health news: After three band purchase selling a pharmaceutical company sales choice resignation band purchase will affect more and more enterprises and individuals.
facing irreversible reform trends, individuals can resign, and businesses can only face it.
Qilu Pharmaceuticals, which has already experienced three band purchases, is a very good observation sample.
headlines: Tape procurement will gradually become the norm.
" Seiber Blue Instruments" National Raid! Supplies rebates, notes, accounts... Recently, Shaanxi Provincial Health and Health Commission issued a "provincial health and health industry style special rectification action plan" notice, the content of the National Health and Health Commission and other 9 ministries "on the issuance of 2020 to correct the pharmaceutical purchase and sale of the field and medical services in the field of improper work points" research and development.
headlines: serious investigation and punishment of the collection of pharmaceutical supplies enterprise rebate behavior.
the "mininet net" Huahai hair! Taking 6 heavyweight varieties 21 overrated varieties Bar screen recently, Huahai Pharmaceuticals released 2020H1 performance forecast, net profit is expected to be 552 million yuan - 620 million yuan, up 65%-85% YoY, preparations and raw materials sales revenue growth has become the main factor driving performance.
headlines: the future.
125 pharmaceutical companies half-yearly report forecast out Ofae bioQ2 month-on-month growth due to the current domestic epidemic is still a local repeat, the global epidemic has not yet ended, therefore, in the market uncertainty caused by the outbreak, the pharmaceutical sector has relative certainty, this can be reflected in the performance of pharmaceutical enterprises reported in the forecast.
headline spour: the layout of the head enterprise under the main line can not be ignored.
Shell Society 50 billion pharmaceutical "white horse" set to increase growth change "package field" of high capital or out? 22 evening, Caley Inn (Securities Code: 002821. SZ) issued a notice that, in view of the current changes in the capital market environment, and take into account the company's actual situation, development planning and many other factors, the previously issued plan to adjust.
this is the focus of this is that the previous package of Kelley Yingding's increase in high-rise capital, from exclusive war investment to "issued to no more than 35 specific investors."
headlines: the market, especially listed companies will no doubt maintain a high degree of attention to this.
Dandelion FDA warning letter: dissolved unqualified can not just modify the standard 21, the FDA official website published a warning letter against a U.S. pharmaceutical company.
one of the company's capsule products in the stability study and sample inspection period, there have been multiple batches of dissolved test failure results.
, the company eventually used a lax quality standard.
the standard was approved in advance by the FDA, the FDA said it was unacceptable because the company had not determined the root cause of the change in solubility and had not implemented the appropriate CAPA, and that there were still many failures after the revision of quality standards.
the headline bacteria: multi-batch dissolution degree is not qualified.
.